Federal Register #2026-16544

Licensing Opportunity: Government-Owned Spironolactone Analogues for Anti-Inflammatory Therapeutics

The Department of Health and Human Services, through the National Institutes of Health and the National Heart, Lung, and Blood Institute (NHLBI), is offering government-owned spironolactone analogues for licensing. - Government Buyer: - Department of Health and Human Services - National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI) - OEMs and Vendors: - No commercial OEMs or vendors; products are government-owned - Products/Services Requested: - Novel spironolactone analogues (anti-inflammatory therapeutics) - Patent rights: NIH Reference No. E02920260US01 - Intended for treatment of chronic inflammatory conditions (atherosclerosis, autoimmune diseases, chronic inflammatory lung disease, pulmonary arterial hypertension, lupus erythematosus, rheumatoid arthritis, COPD, asthma) - Early stage of development; in vitro data available - Unique/Notable Requirements: - Licensing opportunity for commercialization - Confidential Disclosure Agreement required to access unpublished information - Focus on promoting public health benefits through new therapeutics

Description

This notice announces the availability of government-owned inventions for licensing to promote the commercialization of federally-funded research results for public health benefits. Specifically, it highlights novel spironolactone analogues developed by the National Heart, Lung, and Blood Institute as anti-inflammatory therapeutics. These compounds offer potential treatments for various chronic inflammatory conditions such as atherosclerosis, autoimmune diseases, and chronic inflammatory lung disease. The notice is issued by the Department of Health and Human Services, National Institutes of Health.

View original listing